MedTrace Logo

Study on New Strategies for Hepatitis B Virus Immunization

NCT06515938 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1169

Last updated 2024-07-24

No results posted yet for this study

Summary

To investigate the immunogenicity of HB vaccine with different series among primary immune adults aged 25-55, to assess potential alternative approaches for HB immunization.

Conditions

  • Vaccine Reaction

Interventions

BIOLOGICAL

20μg Engerix-B hepatitis B vaccine

BIOLOGICAL

20μg Kangtai hepatitis B vaccine

BIOLOGICAL

60μg Kangtai hepatitis B vaccine

BIOLOGICAL

20μg CHO

Sponsors & Collaborators

  • Wu Jiang

    lead OTHER_GOV

Principal Investigators

  • Wei Zhang · Beijing Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2014-06-30
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06515938 on ClinicalTrials.gov